Role of MKP-1 in Osteoclasts and Bone Homeostasis
Authors:
- Weiguo CuiWCWeiguo Cui
- Qing ZhangQZQing Zhang
- Xiaoqing XuXXXiaoqing Xu
- Fatih MercanFMFatih Mercan
- Anton M. BennettABAnton M. Bennett
- Agnès VigneryAVAgnès Vignery
- 1 October 2009
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 175 (4) , 1564-1573
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (AR46504, DE12110)
This publication has 31 references indexed in Scilit:
- Corticosteroid receptors, macrophages and cardiovascular diseaseJournal of Molecular Endocrinology, 2009
- Signal transduction by receptor activator of nuclear factor kappa B in osteoclastsBiochemical and Biophysical Research Communications, 2003
- Mechanisms balancing skeletal matrix synthesis and degradationBiochemical Journal, 2002
- Estrogen Decreases Osteoclast Formation by Down-regulating Receptor Activator of NF-κB Ligand (RANKL)-induced JNK ActivationJournal of Biological Chemistry, 2001
- Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)Journal of Biological Chemistry, 2000
- The Osteoblast: A Sophisticated Fibroblast under Central SurveillanceScience, 2000
- RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolismProceedings of the National Academy of Sciences, 2000
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProceedings of the National Academy of Sciences, 1998
- Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts.1996